New-fill used to treat lipoatropy in feet
12 June 2008. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Conference reports
Effect of 100mg ritonavir once- and twice-daily on lipids and cardiovascular markers in HIV-negative volunteers
12 June 2008. Related: Conference reports.
15th Conference on Retroviruses and Opportunistic Infections, Boston, 2-6 February 2008
12 June 2008. Related: Conference reports.
Immediate HAART reduces death and AIDS progression over 48 weeks in patients with acute OIs
12 June 2008. Related: Conference reports, Coinfections and complications.
Utility of routine viral load, CD4 count and clinical monitoring among HIV-positive adults in rural Uganda
12 June 2008. Related: Conference reports, Treatment access.
Implementation of more complex regimens for prevention of mother-to-child transmission of HIV in Rwanda
12 June 2008. Related: Conference reports, Treatment access.
The estimated cost of switching from d4T to TDF in South Africa
12 June 2008. Related: Conference reports, Treatment access.
Gender differences in viral load by CD4 count in men and women
12 June 2008. Related: Conference reports, Women's health.
Immune reconstitution inflammatory syndrome in young children initiating ART
12 June 2008. Related: Conference reports, Paediatric care.
Complications with BCG vaccination in HIV-positive and negative infants: CHER Study
12 June 2008. Related: Conference reports, Paediatric care.
The association between clinical characteristics and HIV-infection in very young infants
12 June 2008. Related: Conference reports, Paediatric care.
Safety and efficacy of boosted darunavir in treatment-experienced children and adolescents at 24 weeks
12 June 2008. Related: Conference reports, Paediatric care.
Responses to atazanavir-containing HAART in treatment-naive children in South Africa
12 June 2008. Related: Conference reports, Paediatric care.
Initial growth, CD4, and viral load responses to HAART in Ugandan compared to UK/Irish HIV-positive children
12 June 2008. Related: Conference reports, Paediatric care.
Paediatric pharmacokinetic studies
12 June 2008. Related: Conference reports, Paediatric care.
A pilot study of three treatment strategies for HIV-positive infants
12 June 2008. Related: Conference reports, Paediatric care.
15th Conference on Retroviruses and Opportunistic Infections, 2-6 February 2008, Boston
2 April 2008. Related: Conference reports.
Atazanavir/r vs lopinavir/r in treatment-naive patients: 48 week results
1 April 2008. Related: Conference reports, Antiretrovirals.
Baseline inflammation and coagulation markers and changes over four weeks during a treatment interruption are strongly linked to HIV viraemia and risk of mortality
1 April 2008. Related: Conference reports.
Restarting treatment after an interruption reduces the risk of serious events but CD4 recovery falls short of baseline levels
1 April 2008. Related: Conference reports.
Very low rate of MTCT in women on HAART in UK and Ireland who achieve viral suppression
1 April 2008. Related: Conference reports, Pregnancy.
Predictors of mother to child transmission among women initiating HAART in pregnancy in a South African cohort
1 April 2008. Related: Conference reports, Pregnancy.
Maternal and infant outcomes from the DREAM programme
1 April 2008. Related: Conference reports, Pregnancy.
Nevirapine-resistant HIV present in the latent reservoir following single-dose nevirapine for MTCT prevention
1 April 2008. Related: Conference reports, Pregnancy.
Tenofovir plus FTC reduce NNRTI resistance following single dose nevirapine
1 April 2008. Related: Conference reports, Pregnancy.
Response to treatment after single dose NVP exposure in women
1 April 2008. Related: Conference reports, Pregnancy.
Response to treatment after single dose NVP exposure in infants
1 April 2008. Related: Conference reports, Pregnancy.
Other studies looking at birth outcomes
1 April 2008. Related: Conference reports, Pregnancy.
Infant prophylaxis for postnatal transmission
1 April 2008. Related: Conference reports, Pregnancy.
Antiretroviral drug concentrations in breast milk and breastfeeding infants
1 April 2008. Related: Conference reports, Pregnancy.
Maternal breastfeeding prophylaxis
1 April 2008. Related: Conference reports, Pregnancy.
Risk factors for breastfeeding transmission
1 April 2008. Related: Conference reports, Pregnancy.
UK cohort reports sexual HCV reinfection in at least 5% HIV-positive gay men following sustained response to treatment
1 April 2008. Related: Conference reports, Hepatitis coinfection.
MELD score predictive of pre-transplant mortality in HCV coinfected patients
1 April 2008. Related: Conference reports, Hepatitis coinfection.
Does abacavir decrease SVR rates with HCV treatment?
1 April 2008. Related: Conference reports, Hepatitis coinfection.
No effect of interferon maintenance therapy on fibrosis progression in non-responders
1 April 2008. Related: Conference reports, Hepatitis coinfection.
Stem cell transplant from HLA-matched CCR5-delta 32 deleted donor suppresses viraemia in recipient for 8 months without HAART
1 April 2008. Related: Conference reports, Basic science and immunology.
Risk factors for AIDS-defining and non AIDS-defining cancers
1 April 2008. Related: Conference reports, Cancer and HIV.
CROI 2008 – 12 key areas of research: non-technical summary of 25 studies and presentations
28 February 2008. Related: Special reports, Conference reports.
15th Conference on Retroviruses and Opportunistic Infections, 2-6 February 2008, Boston
1 February 2008. Related: Conference reports.
Increased risk of myocardial infarction associated with abacavir and ddI
1 February 2008. Related: Conference reports.
Position statement by the D:A:D steering committee
1 February 2008. Related: Conference reports.
3rd International Workshop on Targeting HIV Entry, 7-9 December 2007, Washington DC
1 February 2008. Related: Conference reports.
CXCR4-using HIV found in 8.5% during early HIV infection
1 February 2008. Related: Conference reports.
Background drugs and low maraviroc levels explain resistance in Motivate studies
1 February 2008. Related: Conference reports, Drug resistance.
38th World Conference on Lung Health of the Union Against TB and Lung Disease, December 2007, Cape Town
1 February 2008. Related: Conference reports.
Treatment outcomes in patients who received rifampicin with nevirapine or efavirenz
1 February 2008. Related: Conference reports, TB coinfection.
11th European AIDS conference (EACS), October 24-27 2007, Madrid
2 December 2007. Related: Conference reports.
New European guidelines launched (2007)
2 December 2007. Related: Conference reports, Guidelines.
Saquinavir/r non-inferior to Kaletra at week 48 (Gemini study)
2 December 2007. Related: Conference reports, Antiretrovirals.
Darunavir once-daily is non-inferior to lopinavir/r in treatment-naive patients at 48 weeks (Artemis study)
2 December 2007. Related: Conference reports, Antiretrovirals.
Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results
2 December 2007. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Drug interaction studies presented at EACS
1 December 2007. Related: Conference reports, PK and drug interactions, Basic science and immunology.
BHIVA Autumn conference, 11-12 October 2007, London
29 October 2007. Related: Conference reports.
Audit of treating naive patients showed basic UK guidelines not followed in over 25% patients; 60% patients start with a CD4 count <200 cells/mm3
2 October 2007. Related: Conference reports.
4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 22-25 July 2007, Sydney
3 September 2007. Related: Conference reports.
HIV viraemia may explain increased risk of cardiovascular disease, death and other serious events in people interrupting treatment in the SMART trial: new study to randomise people with CD4 counts >500 to start immediate treatment or defer to <350 cells/mm3
3 September 2007. Related: Conference reports, Treatment strategies.
CD4 increases in immunological non-responders despite suppressive therapy following switch to nuke-sparing regimen of ATZ/SQV/r
3 September 2007. Related: Conference reports, Treatment strategies.
Darunavir/r shows superiority over lopinavir/r at 48 weeks in TITAN trial
3 September 2007. Related: Conference reports, Antiretrovirals.
Maraviroc fails to show non-inferiority to efavirenz in treatment-naive patients: 48 week results
3 September 2007. Related: Conference reports, Antiretrovirals.
Importance of using maraviroc in combination with other active drugs in treatment-experienced patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Week 48 raltegravir results in treatment-naive phase II dose-finding study
3 September 2007. Related: Conference reports, Antiretrovirals.
DUET studies clarify antiviral efficacy of etravirine and cross-resistance profile to other NNRTIs
3 September 2007. Related: Conference reports, Antiretrovirals.
Boosting atazanavir in treatment-naive patients, and impact on lipids after switching from lopinavir/r
3 September 2007. Related: Conference reports, Antiretrovirals.
Saquinavir/r vs lopinavir/r in treatment-naive patients
3 September 2007. Related: Conference reports, Antiretrovirals.